Navigation Links
Results of the PROFI study reported at TCT 2011
Date:11/11/2011

SAN FRANCISCO, CA NOVEMBER 11, 2011 Results from the PROFI study indicate that the use of a proximal balloon occlusion in carotid artery stenting lead to fewer cerebral ischemic lesions a predictor of stroke than with the use of a filter. Trial results were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

Previous randomized trials have revealed a higher rate of stroke following carotid artery stenting when compared to surgical removal of plaque from the carotid artery. One of the reasons for this may be that the use of filters in carotid artery stenting allows plaque particles to travel to the brain. PROFI is the first randomized trial comparing proximal balloon occlusion with filter protection in patients undergoing carotid artery stenting

In the PROFI (Prevention of Cerebral Embolization by PROximal Balloon Occlusion Compared to FIlter Protection During Carotid Artery Stenting) trial, 62 patients undergoing carotid artery stenting with cerebral embolic protection for a ≥ 60 % symptomatic or ≥ 80% asymptomatic internal carotid artery stenosis were randomly assigned to proximal balloon occlusion or filter protection. The primary endpoint was the incidence of new cerebral ischemic lesions as assessed by diffusion weighted magnetic resonance imaging (DW-MRI). Secondary endpoints were the number and volume of new ischemic lesions and major adverse cardiovascular and cerebral events (MACCE).

The incidence rate of new cerebral ischemic lesions was 87.1%in the filter group, and 45.2% in the balloon group. The mean number of new cerebral ischemic lesions was 3.5 in the filter group and 1.0 in the balloon group. There were no significant differences in MACCE at 30 days between the two groups.

"In this single center, randomized trial in patients undergoing carotid artery stenting, the incidence, number, and volume of new cerebral ischemic lesions were significantly lower under proximal balloon protection than under filter protection," said Joachim Schofer, MD, Professor of Medicine, at the Medical Care Center, Professor Mathey, Professor Schofer, Hamburg University Cardiovascular Center.

"A larger randomized trial with clinical endpoints is needed to investigate whether this benefit translates into a reduced periprocedural stroke rate," said Dr. Schofer.


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Results of the EVOLVE trial reported at TCT 2011
2. Results of the REMEDEE trial reported at TCT 2011
3. Results of the NEXT clinical trial Reported at TCT 2011
4. Results of the PEPCAD-DES trial reported at TCT 2011
5. Results of the STACCATO Trial reported at TCT 2011
6. Results of the DEB-AMI Trial reported at TCT 2011
7. Results of the RIFLE STEACS clinical trial reported at TCT 2011
8. Results of the PARTNER Trial Cohort B 2-year follow up presented at TCT 2011
9. Results of the PARTNER Trial Cohort A cost effectiveness analysis reported
10. Combination epigenetic therapy clinical trial results
11. Results of the PARIS registry Reported at TCT 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... On May 23rd during the National ... Science® and international water advocate, was honored by Ashram, Inc. as the world’s foremost ... who knelt on the banks of the Nile to fill their red clay pots ...
(Date:5/26/2016)... ... May 26, 2016 , ... Saint Francis ... several years, and the efforts have paid off. Since implementation of these ... of care to enhance perioperative patient experiences and reduce costly complications. Since implementation ...
(Date:5/26/2016)... Viejo, California (PRWEB) , ... May 26, 2016 , ... ... Transition Plugin for FCPX. , "This new layered style transition tool will ... said Christina Austion - CEO of Pixel Film Studios. , TranSweep is an ...
(Date:5/26/2016)... ... May 26, 2016 , ... TopConsumerReviews.com recently awarded their ... . , High blood pressure affects millions of people worldwide, and many patients ... lead to heart disease, stroke, kidney disease, and hardening of the arteries. However, ...
(Date:5/25/2016)... ... , ... The United States Food and Drug Administration (FDA) has now cleared ... To date, the company is the first and only manufacturer of low level laser ... androgenetic alopecia. , “This new level of clearance substantiates what many physicians have ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... , May 24, 2016 ... de doble terapia del mundo, introduce catéteres para ... OrbusNeich, una compañía global especializada en ... vidas, ha expandido su cartera incluyendo productos para ... JADE™ y Scoreflex™ PTA son los dispositivos de ...
(Date:5/24/2016)... 2016 Een app die artsen ... collectief patiënten kunnen behandelen, hun kennis kunnen delen en ... de nieuwe en revolutionaire MDLinking App, ontwikkeld door een ... dr. Hans Flu en oncologisch chirurg dr. Gijs ... is, wordt op dinsdag 24 mei officieel gepresenteerd op ...
(Date:5/23/2016)... ALBANY, New York , May 23, 2016 /PRNewswire/ ... new market report titled, " Exocrine Pancreatic Insufficiency Market ... Forecast 2013 - 2023 ." According to the report, ... at a CAGR of 8.3% from 2015 to 2023 ... pancreatic insufficiency (EPI) is a condition characterized by the ...
Breaking Medicine Technology: